Financial Daily from THE HINDU group of publications
Tuesday, Jul 12, 2005

Port Info

Group Sites

Corporate - Alliances & Joint Ventures

Apollo Hospitals ties up with US co for stem cell research

Our Bureau

Chennai , July 11

APOLLO Hospitals on Monday announced its tie-up with Histostem of the US "for the development of a sustaining and mutually beneficial relationship in cord blood stem cell research and therapy in India."

Histostem and Apollo will establish and operate treatment centres, to be called `Histostem Cell Treatment Centres'.

As part of the tie-up, Histostem will train the doctors and nurses at Apollo for stem cell treatment protocols and develop new treatment protocols with a relevant regulatory approach, according to a press release from Apollo.

What is `stem cell'? Research has shown that the blood generated in the umbilical cord — the tube that connects the baby in the womb and the mother — is useful for treatment of some diseases the baby may develop later, in its adulthood.

The release lists a number of diseases that can be cured using the stem cells derived from the umbilical cord blood, such as spinal cord injury, chronic renal failure, diabetes mellitus, cerebral infarction, spino-cerebellar degeneration and Buerger's disease.

"The multi-potent stem cell therapy can be compared to a bone marrow transplant, which is known to be a successful treatment for a variety of malignant, autoimmune and genetic diseases," says the release.

Sensing a business opportunity in this, a number of companies have cropped up in the country, most of which collect and promise to preserve the umbilical cord for several decades.

Apollo has joined the bandwagon, in collaboration with the US company, for both preserving the umbilical cord and for stem cell research.

But those who are enthusiastic about stem cells therapy should know this: it is expensive.

Companies that offer to preserve the umbilical cord of new-borns for later use, charge about Rs 80,000 for the service. Also, several doctors in maternity clinics say stem cell therapy is not yet a fully evolved science and its benefits have yet to be proved.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
M&M launches pick-up utility

FIPB okays GM India's royalty payment plan
Bajaj Hindusthan to pump in Rs 750 cr to expand capacity — Plans 3 greenfield projects in UP
NTPC to invest Rs 500 cr in Ratnagiri Gas
Matrix Lab carries out changes in management structure
Italian co to prepare feasibility report for GAIL pipeline project
CLB adjourns BPL case to July 30
Lodha's claim on M.P. Birla Group profits disputed
Madras HC orders fresh tendering of Standard Motors' assets
Merger of oil PSUs not advisable, says panel
Reliance Capital, REL refute rumours on buys
Jindal South West chalks out Rs 10,000-cr expansion plan
JK Papers on expansion mode; commissions new plant in Orissa
HEG commissions expanded capacity graphite plant in M.P.
Apollo Hospitals ties up with US co for stem cell research
BEML plans to raise Rs 400 cr thru public offer
`Tata Motors will make up for shortfall'
Companies shape products, seek to win by design

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line